Evidence map›Paper›PMID 38464514›Full record

ArticleFrontiers in immunology2024

Superoxide dismutase alterations in COVID-19: implications for disease severity and mortality prediction in the context of omicron variant infection.

Jinshen Chu, Lin Hua, Xiaofeng Liu, Huomei Xiong, Fangtinghui Jiang, Wei Zhou, Lu Wang, Guohui Xue

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Observational
  3. Observational
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Jinshen Chu *Department of Clinical Laboratory, Jiujiang No.1 People's Hospital, Jiujiang, China.
Lin Hua *Department of Clinical Laboratory, Jiujiang No.1 People's Hospital, Jiujiang, China.
Xiaofeng LiuDepartment of Clinical Laboratory, Jiujiang No.1 People's Hospital, Jiujiang, China.
Huomei XiongDepartment of Microbiology, Jiujiang Center for Disease Control and Prevention, Jiujiang, China.
Fangtinghui JiangDepartment of Clinical Laboratory, Jiujiang No.1 People's Hospital, Jiujiang, China.
Wei ZhouDepartment of Clinical Laboratory, Jiujiang No.1 People's Hospital, Jiujiang, China.
Lu WangDepartment of Clinical Laboratory, Jiujiang No.1 People's Hospital, Jiujiang, China.
Guohui XueDepartment of Clinical Laboratory, Jiujiang No.1 People's Hospital, Jiujiang, China.
Jiujiang First People's Hospital · CNJiujiang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: In the few reports to date, the changes in superoxide dismutase (SOD), a key factor in cellular protection against superoxide, in COVID-19 have been very inconsistent and contradictory. There is also a lack of data on COVID-19 induced by Omicron variant. Further investigation is warranted to figure out SOD alterations in COVID-19, particularly within the context of ongoing Omicron variant infection, which may provide clues to its role within COVID-19 pathogenesis and open up new avenues for COVID-19 treatment. Methods: SOD activity in 109 COVID-19 patients (including 46 severe cases and 63 mild to moderate cases) and 30 matched healthy controls were quantified. Demographic data, blood cell counts, biochemical indicators, coagulation indicators, and inflammatory markers were also recorded. Results: SOD, an important key node, experienced a significant decrease in COVID-19, with the severe patients exhibiting lower activity compared to the mild to moderate patients and control healthy. Notably, severe patients who deceased had the lowest SOD activity. Correlation analysis revealed significant correlations between SOD and inflammatory markers, organ injury markers, coagulation dysfunction indicators, nutritional markers, and lymphocytes counts. The ROC curve also showed good performance for the differentiation of severe cases and the prediction of death. Conclusion: SOD activity was significantly decreased in COVID-19 infected with Omicron variant and significantly correlated with systemic changes, and could be used as a biomarker to assess disease severity and predict mortality in COVID-19 clinical pathway management. Additionally, this finding will contribute to exploring new potential direction for the treatment of severe COVID-19 patients.

Indexed as

COVID-19Superoxide DismutaseCOVID-19 Drug TreatmentHumansPatient AcuitySARS-CoV-2Superoxide DismutasebiomarkerCOVID-19disease severityomicron variantsuperoxide dismutase

Identifiers

PMID38464514
PMCPMC10921560
OpenAlexW4392055109

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.